
Best Biotech PR Agencies 2026: 6 Firms Compared
Biotech PR explained: who it serves, how FDA and SEC rules shape it, the main functions and six agencies worth knowing, with a stage-by-stage selection guide.
Drug approvals, clinical trials, patient advocacy and the agencies behind pharma and biotech communications.
Pharma PR and marketing earns trust for medicines, the companies that make them and the patients who use them, under FDA promotion rules. GLP-1 makers and telehealth sellers spent more than $1.1 billion on national TV ads in 2025, per iSpot.tv data. This hub covers ad rules, campaigns, agencies and AI visibility.


Biotech PR explained: who it serves, how FDA and SEC rules shape it, the main functions and six agencies worth knowing, with a stage-by-stage selection guide.






GLP-1 brand communications: Ozempic, Wegovy, Mounjaro and Zepbound citation share, pricing and access, the $50 Medicare Bridge, supply and pipeline narratives, and AI answers.

Pfizer's 2016 corporate campaign put scientists like Mark Noe on camera instead of selling a drug. What it did, why it worked and what pharma teams can copy.

EPR's Pharma hub: the $8B DTC ad spend, the GLP-1 category, the Pharma AI Citation Share Study, company profiles for Pfizer, Merck, Lilly, Novo Nordisk and J&J, and how AI answers drug questions.
Pharma PR and marketing is the work of earning trust for medicines, the companies that make them and the patients who use them. It combines earned media, advertising, patient education and regulator-safe messaging. The category is led by brands such as Eli Lilly and Novo Nordisk, and by the healthcare PR firms ranked in EPR’s 20 best healthcare PR agencies. GLP-1 drug makers and telehealth sellers spent more than $1.1 billion on national TV ads in 2025, nearly one-fifth of all pharma linear TV spending, according to iSpot.tv data provided to eMarketer. This hub collects EPR’s pharma guides, campaign lists, case studies and AI visibility research. It describes marketing, not medical guidance.
Key facts
Pharma PR and marketing covers five jobs, and each one runs under different rules. The table shows who is involved and what the work is for.
| Segment | Who is involved | Main rules | Typical goal |
|---|---|---|---|
| Prescription brand promotion | Brand teams, ad agencies, PR firms | FDA promotion rules, fair balance | Awareness and appropriate use |
| Biotech and clinical-stage companies | Founders, investor relations, PR firms | SEC disclosure, FDA review | Credibility with investors and clinicians |
| Corporate reputation | Communications and policy teams | Securities and public affairs rules | Trust in the company |
| Patient education and advocacy | Patient groups, brand and medical teams | FDA and FTC claim rules | Informed patients |
| Pricing and access | Communications, government affairs | Federal and state policy | Clear access information |
For the agency side, see EPR’s biotech PR guide and the healthcare PR agency ranking.
The FDA raised the bar for drug advertising on September 9, 2025. The agency announced what it called a crackdown on misleading direct-to-consumer ads, sent templated letters that it described as going to thousands of drug companies, and issued about 100 cease-and-desist letters aimed at specific products. A law firm tally of the 61 enforcement letters posted from September counted 8 warning letters and 53 untitled letters, and 38 of them targeted DTC television ads. Legal commentators also note that the FDA signaled a return to hundreds of letters a year, up from 10 to 20 untitled letters annually.
Teams that built clear, balanced creative before the announcement are best placed. A practical sequence:
GLP-1 medicines are the most visible marketing story in pharma. Beyond the $1.1 billion in 2025 TV spend, IQVIA data shared by a Wall Street analyst showed Zepbound prescriptions passing Wegovy in 2025, which gave Eli Lilly about 60% of the U.S. weight-loss drug market, as summarized in EPR’s 25 GLP-1 marketing campaigns and moves. Novo Nordisk and Lilly each reached a pricing agreement with the administration in November 2025, according to Fierce Pharma. A 2024 BMJ news report counted a 700% rise over four years in U.S. patients without diabetes starting GLP-1 treatment (Mahase, BMJ 2024), which helps explain why wellness marketers now treat these medicines as a starting assumption.
Eli Lilly and Novo Nordisk lead in AI answers. EPR’s coverage of the AI Visibility Index from 5W Public Relations, a PR, creative and GEO agency, ranks the top 25 drugmakers by citation share across ChatGPT, Claude, Perplexity, Gemini and Google AI Overviews. Pharma spends about $8 billion a year on direct-to-consumer ads, yet the engines still cited Eli Lilly most often. Merck makes the world’s top-selling drug and ranks fifth. The full study is in Pharma Spent $8 Billion on TV. The Chatbox Cited Eli Lilly Anyway.
Five shifts are changing how drugmakers plan and defend their communications.
Direct-to-consumer pricing now sits next to advertising and PR as a way to reach patients. Brand and communications teams explain price and access in plain language alongside the creative.
Commentators note the FDA has issued untitled letters over influencer posts that miss fair balance rules. Creator programs now need the same review as any other ad.
Patients, reporters and investors ask answer engines about a medicine before they read a press release. Clear first-party facts and strong earned coverage give those engines good sources to cite.
Eli Lilly’s U.S. manufacturing buildout of more than $20 billion shows how supply and investment stories support a brand’s reputation, as covered in EPR’s pharma research.
Leading brands now manage a citation environment as well as a media environment. Tracking which sources the engines cite helps leaders keep their facts accurate over time.
Programs hold up when claims are clear, sources are public and the response plan exists before it is needed. The table lists the moves that matter most.
| Play | Action | Why it works |
|---|---|---|
| Build one claims library | Approve claims once and reuse them across PR, brand and agencies | Consistent claims are easier to defend |
| Review creator content | Apply fair-balance review to influencer posts | Creator posts are part of the record |
| Publish first-party facts | Put pricing, access and safety facts on the company site | Engines and reporters cite primary sources |
| Track AI citations | Check the five engines monthly for brand and product questions | Early view of what patients read |
| Plan the crisis response | Draft holding statements and a recall protocol in advance | A fast, calm response protects trust |
The 1982 Tylenol response remains the reference case for a calm, patient-first crisis reply. EPR covers it in Tylenol Crisis History.
Everything-PR News, LLC and 5W Public Relations share a common ownership group. Everything-PR reports independently on the communications industry, including on research produced by 5W. Editorial decisions are made by Everything-PR's editorial team.